Ann: Investor Webinar featuring COO, Dr Glover & CMO, Dr Woodard, page-107

Imugene (ASX:IMU)

There’s been a bit of news flow coming out of Imugene in the last couple of weeks.

First, the company reported that its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial evaluating novel cancer-killing virus CF33-hNIS (VAXINIA) showed that all treatments to date have been determined safe and tolerable.

As of 31 October, 34 patients have been dosed with VAXINIA during the continuing dose escalation phase.

Imugene also announced dosing of the first patient in a Phase 1b clinical trial using azer-cel (allogeneic off-the-shelf CD19 CAR T, a type of cell therapy), manufactured and supplied from its state-of-the-art facility in North Carolina.

Following completion of the Phase 1b study, Imugene says there is potential to start this therapy as a registrational study in 2024. and become the first approved allogeneic CAR T cell therapy for cancer.

Just spreading the love